Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin201161699021296855
   PubMed Web of Science ®Google Scholar
• MarurSForastiereAAHead and neck cancer: changing epidemiology, diagnosis, and treatmentMayo Clin Proc200883448950118380996
   PubMed Web of Science ®Google Scholar
• GötteKUsenerDRiedelFHörmannKSchadendorfDEichmüllerSTumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genesActa Otolaryngol2002122554655212206267
   PubMed Web of Science ®Google Scholar
• YoungMRNevilleBWChiACLathersDMBoyd GillespieMDayTAOral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinomaCancer Immunol Immunother20075671077108617096152
   PubMedGoogle Scholar
• HartmannSKipkeRURautheSOral brush biopsy and melanoma-associated antigens A (MAGE-A) staining in clinically suspicious lesionsJ Craniomaxillofac Surg201543102214221826589180
   PubMedGoogle Scholar
• MerckFDA approves KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapyKenilworth, NJ, USAMerck2015102 Available from: http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-keytruda-pembrolizumab-treatment-patients-metasAccessed October 25, 2015
   Google Scholar
• Food and Drug AdministrationFDA approves Yervoy to reduce the risk of melanoma returning after surgery [press release]Silver Spring, MDUS FDA20151028 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htmAccessed February 29, 2016
   Google Scholar
• MilsteinOHaginDLaskACTLs respond with activation and granule secretion when serving as targets for T-cell recognitionBlood201111731042105221045195
   PubMedGoogle Scholar
• JoshiRPKoretzkyGADiacylglycerol kinases: regulated controllers of T cell activation, function, and developmentInt J Mol Sci20131446649667323531532
   PubMedGoogle Scholar
• MischingerJComperatESchwentnerCStenzlAGakisGInflammation and cancer: what can we therapeutically expect from checkpoint inhibitors?Curr Urol Rep2015165926141938
   PubMed Web of Science ®Google Scholar
• JungKChoiIEmerging co-signaling networks in T cell immune regulationImmune Netw201313518419324198743
   PubMedGoogle Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• FranciscoLMSalinasVHBrownKEPD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJ Exp Med20092063015302920008522
   PubMed Web of Science ®Google Scholar
• HeYFZhangGMWangXHBlocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokineJ Immunol20041734919492815470033
   PubMed Web of Science ®Google Scholar
• ThompsonRHGillettMDChevilleJCCostimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic targetProc Natl Acad Sci U S A2004101171741717915569934
   PubMed Web of Science ®Google Scholar
• BolandJMKwonEDHarringtonSMTumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lungClin Lung Cancer20131415716322868219
   PubMed Web of Science ®Google Scholar
• VelchetiVSchalperKACarvajalDEProgrammed death ligand-1 expression in non-small cell lung cancerLab Invest20149410711624217091
   PubMed Web of Science ®Google Scholar
• CooperWATranTVilainREPD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinomaLung Cancer20158918118826024796
   PubMedGoogle Scholar
• HuangYZhangSDMcCruddenCChanKWLinYKwokHFThe prognostic significance of PD-L1 in bladder cancerOncol Rep2015333075308425963805
   PubMed Web of Science ®Google Scholar
• KakavandHVilainREWilmottJSTumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastasesMod Pathol2015281535154426403784
   PubMed Web of Science ®Google Scholar
• NduomEKWeiJYaghiNKPD-L1 expression and prognostic impact in glioblastomaNeuro Oncol201618219520526323609
   PubMed Web of Science ®Google Scholar
• ChristianJMNor HaslindaAAJayantaCProgrammed death ligand 1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancerCancer Immunol Immunother201463321522424297569
   PubMedGoogle Scholar
• KarwaczKBricogneCMacDonaldDPD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cellsEMBO Mol Med2011358159221739608
   PubMed Web of Science ®Google Scholar
• AmarnathSMangusCWWangJCThe PDL1-PD1 axis converts human TH1 cells into regulatory T cellsSci Transl Med20113111120
   Web of Science ®Google Scholar
• BrunetJFDenizotFLucianiMFA new member of the immunoglobulin superfamily – CTLA-4Nature198732861272672703496540
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in Ctla-4Science199527052389859887481803
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4Immunity199535415477584144
   PubMed Web of Science ®Google Scholar
• LenschowDJHeroldKCRheeLCD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetesImmunity1996532852938808683
   PubMed Web of Science ®Google Scholar
• LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJACTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med19911745615691714933
   PubMed Web of Science ®Google Scholar
• LinsleyPSGreeneJLBradyWBajorathJLedbetterJAPeachRHuman B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity1994197938017534620
   PubMed Web of Science ®Google Scholar
• van der MerwePABodianDLDaenkeSLinsleyPDavisSJCD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kineticsJ Exp Med199718533934039053440
   PubMed Web of Science ®Google Scholar
• LeeKMChuangEGriffinMMolecular basis of T cell inactivation by CTLA-4Science19982825397226322669856951
   PubMed Web of Science ®Google Scholar
• FallarinoFFieldsPEGajewskiTFB7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28J Exp Med19981882052109653097
   PubMed Web of Science ®Google Scholar
• MastellerELChuangEMullenACReinerSLThompsonCBStructural analysis of CTLA-4 function in vivoJ Immunol20001645319532710799894
   PubMed Web of Science ®Google Scholar
• SchneiderHDowneyJSmithAReversal of the TCR stop signal by CTLA-4Science20063131972197516931720
   PubMed Web of Science ®Google Scholar
• TakahashiTTagamiTYamazakiSImmunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4J Exp Med200019230330910899917
   PubMed Web of Science ®Google Scholar
• WingKOnishiYPrieto-MartinPCTLA-4 control over Foxp3+ regulatory T cell functionScience2008322589927127518845758
   PubMed Web of Science ®Google Scholar
• FarkonaSDiamandisEPBlasutigIMCancer immunotherapy: the beginning of the end of cancer?BMC Med20161417327151159
   PubMed Web of Science ®Google Scholar
• ZandbergDPStromeSEThe role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neckOral Oncol20145062763224819861
   PubMed Web of Science ®Google Scholar
• MontlerRBellRBThalhoferCOX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancerClin Transl Immunol201654e70
   PubMedGoogle Scholar
• MalmIJBrunoTCFuJExpression profile and in vitro blockade of programmed death-1 in human papilloma virus-negative head and neck squamous cell carcinomaHead Neck20153781088109524710745
   PubMed Web of Science ®Google Scholar
• ChoYAYoonHJLeeJIHongSPHongSDRelationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinomaOral Oncol2011471148115321911310
   PubMed Web of Science ®Google Scholar
• ChikamatsuKSakakuraKToyodaMTakahashiKYamamotoTMasuyamaKImmunosuppressive activity of CD14+ HLA-DR-cells in squamous cell carcinoma of the head and neckCancer Sci2012103697698322360618
   PubMed Web of Science ®Google Scholar
• ZaravinosAAn updated overview of HPV-associated head and neck carcinomasOncotarget20145123956396924970795
   PubMedGoogle Scholar
• Lyford-PikeSPengSYoungGDEvidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaCancer Res20137361733174123288508
   PubMed Web of Science ®Google Scholar
• UkpoOCThorstadWLLewisJSJrB7-H1 expression model for immune evasion in human papilloma virus-related oropharyngeal squamous cell carcinomaHead Neck Pathol20137211312123179191
   PubMedGoogle Scholar
• MalaspinaTSGasparotoTHCostaMREnhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinomaCancer Immunol Immunother20116096597421442435
   PubMedGoogle Scholar
• ZhangPOuyangSWangJHuangZWangJLiaoLLevels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implicationsHua Xi Kou Qiang Yi Xue Za Zhi2015335529533 Chinese26688950
   PubMedGoogle Scholar
• HsuMCHsiaoJRChangKCIncrease of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinomaMod Pathol2010231393140320657553
   PubMed Web of Science ®Google Scholar
• ZhangFLiuZCuiYWangGCaoPThe clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinomaLin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2008229408410 Chinese18652314
   PubMedGoogle Scholar
• CaoPCuiYLiuZZhangFExpression and significance of PD-L1 in laryngocarcinomaLin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2008222411151116 Chinese19297851
   PubMedGoogle Scholar
• MariaVMargaritisAVamsidharVEvaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinomaClin Cancer Res201622370471326408403
   PubMedGoogle Scholar
• TanLLiJAndomDExpression of PD-1, CD45RO and OX40 in esophageal squamous cell carcinoma tissueJ Zhengzhou Univ (Med Sci)2014492141145
   Google Scholar
• MengQExpression of B7-H1 in Esophageal Carcinoma and its Impact on T Cell FunctionZhengzhouZhengzhou University200812
   Google Scholar
• JieH-BGildener-LeapmanNLiJIntratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patientsBr J Cancer2013109102629263524169351
   PubMed Web of Science ®Google Scholar
• ErfaniNKhademiBHaghshenasMRMojtahediZKhademiBGhaderiAIntracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinomaImmunol Invest2013422819023252863
   PubMed Web of Science ®Google Scholar
• HuangPYGuoSSZhangYTumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinomaOncotarget2016711130601306826918337
   PubMedGoogle Scholar
• ZhangXFPanKWengDSCytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosisOncotarget2016718266702667927050369
   PubMedGoogle Scholar
• SunTZhouYYangMFunctional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancerCancer Res2008687025703418757416
   PubMed Web of Science ®Google Scholar
• UedaHHowsonJMEspositoLAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature200342350651112724780
   PubMed Web of Science ®Google Scholar
• KämmererPWToyoshimaTSchöderFAssociation of T-cell regulatory gene polymorphisms with oral squamous cell carcinomaOral Oncol201046754354820435510
   PubMedGoogle Scholar
• WongYKChangKWChengCYLiuCJAssociation of CTLA-4 gene polymorphism with oral squamous cell carcinomaJ Oral Pathol Med2006351515416393254
   PubMed Web of Science ®Google Scholar
• LiuCWangYJiangHAssociation between cytotoxic T-lymphocyte antigen 4 (CTLA-4) +49 G.A (rs231775) polymorphism and esophageal cancer: from a case-control study to a meta-analysisInt J Clin Exp Med2015810176641767326770356
   PubMedGoogle Scholar
• XiaoMQiFChenXFunctional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese populationInt J Immunogenet2010371273219922464
   PubMed Web of Science ®Google Scholar
• AdachiKTamadaKImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacyCancer Sci2015106894595025981182
   PubMedGoogle Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• RamanRVaenaDImmunotherapy in metastatic renal cell carcinoma: a comprehensive reviewBiomed Res Int2015201536735426161397
   PubMedGoogle Scholar
• FordePMReissKAZeidanAMBrahmerJRWhat lies within: novel strategies in immunotherapy for non-small cell lung cancerOncologist201318111203121324105749
   PubMedGoogle Scholar
• IntlekoferAMThompsonCBAt the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJ Leukoc Biol2013941253923625198
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• EconomopoulouPPerisanidisCGiotakisEIPsyrriAThe emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applicationsAnn Transl Med20164917327275486
   PubMed Web of Science ®Google Scholar
• PageDBPostowMACallahanMKWolchokJDCheckpoint modulation in melanoma: an update on ipilimumab and future directionsCurr Oncol Rep201315550050823933888
   PubMed Web of Science ®Google Scholar
• JieHBSchulerPJLeeSCCTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosisCancer Res201575112200221025832655
   PubMed Web of Science ®Google Scholar
• ArandaFVacchelliEEggermontATrial watch immunostimulatory monoclonal antibodies in cancer therapyOncoimmunology20143e2729724701370
   PubMed Web of Science ®Google Scholar
• SeiwertTYHaddadRIGuptaSAntitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohortJ Clin Oncol201533LBA6008
   Google Scholar
• BaumlJMCohenRBAggarwalCImmunotherapy for head and neck cancer: latest developments and clinical potentialTher Adv Med Oncol20168316817527239235
   PubMedGoogle Scholar
• SeiwertTYBurtnessBMehraRSafety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialLancet Oncol201617795696527247226
   PubMed Web of Science ®Google Scholar
• ChowLQBurtnessBWeissJA phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with human papilloma virus (HPV)-positive and negative head and neck cancer (HNC)Ann Oncol2014255141
   Google Scholar
• HamanishiJMandaiMMatsumuraNAbikoKBabaTKonishiIPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesInt J Clin Oncol20162146247326899259
   PubMed Web of Science ®Google Scholar
• ChervinCSBrocksteinBCurrent clinical immunotherapeutic approaches for head and neck cancerF1000Res Epub201655
   Google Scholar
• HangWXuZXZhangQLuXLiuGImmune checkpoint inhibitor therapy in advanced head and neck cancerZhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi20175216770 Chinese28104022
   PubMedGoogle Scholar
• ArgirisAHarringtonKJTaharaMEvidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neckFront Oncol201777228536670
   PubMed Web of Science ®Google Scholar